Yhdysvallat - englanti - NLM (National Library of Medicine)

putney, inc. - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg - enrofloxacin flavored tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enrofloxacin flavored tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

Yhdysvallat - englanti - NLM (National Library of Medicine)

darmerica - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 1 kg in 1 kg

Yhdysvallat - englanti - NLM (National Library of Medicine)

attix pharmaceuticals - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 5 kg in 5 kg

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

animedica gmbh - enrofloxacin - solution for injection - 25 milligram(s)/millilitre - enrofloxacin

Yhdysvallat - englanti - NLM (National Library of Medicine)

mwi/vetone - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin flavored tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. enrofloxacin flavored tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

animedica gmbh - enrofloxacin - oral solution - 25 milligram(s)/millilitre - enrofloxacin - cattle - antibacterial

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

forte healthcare ltd - enrofloxacin - solution for injection - 25 milligram(s)/millilitre - enrofloxacin - cats, dogs, gerbils, hamsters, other birds, rabbits, reptiles - antibacterial

Yhdysvallat - englanti - NLM (National Library of Medicine)

darmerica - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) -

Yhdysvallat - englanti - NLM (National Library of Medicine)

kdg impresa llc, aqion - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) -

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

animedica gmbh - enrofloxacin - solution for injection - 100 milligram(s)/millilitre - enrofloxacin